title: Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
authors.affiliation: CNR Institute of Clinical Physiology, Pisa, Italy ferranni@ifc.cnr.it.
authors.forename: Ele
authors.initials: E
authors.lastname: Ferrannini
authors.affiliation: Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Mark
authors.affiliation: Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
authors.forename: Eric
authors.initials: E
authors.lastname: Mayoux
mesh_terms: D006801:Humans; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2
chemical_list: D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2